Palvella Therapeutics Submits Initial Module of NDA for QTORIN

Palvella Therapeutics (NASDAQ:PVLA) submitted the initial module of its New Drug Application (NDA) to the FDA for approval of QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations. The company plans to complete the NDA process in late 2026 and aims for potential commercial launch by early 2027 if approved.

By Muhammad Ali Khalid Wed, July 15, 2026 at 5:01 PM GMT+3 2 min read · Yahoo Finance · July 15, 2026, 14:01 UTC

Tickers: $PVLA

Topics: biotech drug approval rare disease treatment

Read the full article at Yahoo Finance

More World news

Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC
Rising New Vehicle Monthly Payments Pose Affordability Risks for Ford and General Motors Motley Fool · November 12, 2026, 16:33 UTC
SpaceX Shares Rise Following Nvidia CEO Jensen Huang Resignation Motley Fool · November 12, 2026, 16:34 UTC
tZERO Receives CFTC Approval for Derivatives Exchange and Clearing Operations PR Newswire · November 12, 2026, 16:36 UTC
enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade Seeking Alpha · November 12, 2026, 16:33 UTC
Former Nvidia CEO Jensen Huang to Testify Before Congress Regarding Export Controls and Security Concerns TechCrunch · November 12, 2026, 16:36 UTC
Nobu Hospitality and Infracorp Partner to Develop Luxury Destination in Bahrain PR Newswire · November 12, 2026, 16:34 UTC
Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC